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Ursodeoxycholic acid (UDCA) treatment can reduce itch and lower endogenous serum bile acids in 31 
intrahepatic cholestasis of pregnancy (ICP). We sought to determine how it could influence the gut 32 
environment in ICP to alter enterohepatic signalling. 33 
The gut microbiota and bile acid content were determined in faeces from 35 pregnant women (14 34 
with uncomplicated pregnancies and 21 with ICP, 17 receiving UDCA). Faecal bile salt hydrolase 35 
activity was measured using a precipitation assay. Serum fibroblast growth factor 19 (FGF19) and 7α-36 
hydroxy-4-cholesten-3-one (C4) concentrations were measured following a standardised diet for 21 37 
hours.  38 
Women with a high ratio of Bacteroidetes to Firmicutes were more likely to be treated with UDCA 39 
(Fisher’s exact test p=0.0178) than those with a lower ratio. Bile salt hydrolase activity was reduced 40 
in women with low Bacteroidetes:Firmicutes. Women taking UDCA had higher faecal lithocholic acid 41 
(p<0.0001), with more unconjugated bile acids than women with untreated ICP or uncomplicated 42 
pregnancy. UDCA-treatment increased serum FGF19, and reduced C4 (reflecting lower bile acid 43 
synthesis).  44 
During ICP, UDCA treatment can be associated with enrichment of the gut microbiota with 45 
Bacteroidetes. These demonstrate high bile salt hydrolase activity, which deconjugates bile acids 46 
enabling secondary modification to FXR agonists, enhancing enterohepatic feedback via FGF19. 47 
 48 
Introduction 49 
The serum and faecal bile acid composition is intimately related to biotransformation of bile acids by 50 
intestinal bacteria, and their subsequent enterohepatic circulation. Deconjugation of primary bile 51 
acids by bacterial bile salt hydrolase (BSH) enables unconjugated bile acids to be modified to 52 
secondary bile acids. Bile acids act as signalling molecules for many different end organs (e.g. liver, 53 
pancreas, adipose tissue, inflammatory cells), with individual bile acid species of differing ligand 54 
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potency for different receptors (e.g. farnesoid X receptor (FXR), Takeda G‐protein‐coupled receptor 55 
5 (TGR5))[1-3]. 56 
Intrahepatic cholestasis of pregnancy (ICP) is predominantly a liver disorder specific to pregnancy, 57 
defined by pruritus and elevated serum bile acids beyond the normal asymptomatic 58 
hypercholanaemia of pregnancy. Fetal adverse outcomes are related to the extent of elevation of 59 
serum concentrations of total bile acids[4,5]. Women with ICP have increased rates of impaired 60 
glucose tolerance, gestational diabetes mellitus, and dyslipidaemia[6,7]. The drug ursodeoxycholic 61 
acid (UDCA) improves itch severity and alters the composition of the serum bile acid pool in ICP[8,9]. 62 
Previous studies have suggested that UDCA may be of additional benefit for women with ICP, for 63 
example by normalising the ICP-related fall in glucagon-like peptide 1 (GLP1) release following a 64 
meal[6]. Indeed, murine studies have demonstrated that UDCA treatment can lower blood glucose 65 
concentrations in mice fed a high-fat diet[10].  66 
A number of studies have established that the gut microbiota changes during pregnancy, and this 67 
can be associated with the gestational metabolic alterations observed in late pregnancy[11–13]. We 68 
hypothesised that the metabolic improvements associated with UDCA treatment of ICP are 69 
contributed to by the beneficial effects of an altered intestinal microbiota, providing enhanced 70 
enterohepatic feedback. Human studies of the intestinal microbiota are complicated by inter-71 
individual differences in diet, environment and genetics. Furthermore, the composition of the 72 
intestinal content must be inferred from faecal samples, particularly during pregnancy when 73 
endoscopy for research is relatively contra-indicated. We therefore used a murine model to further 74 
interrogate the effects observed in humans. Cholic acid (CA) dietary supplementation has previously 75 
been demonstrated to result in serum bile acid concentrations comparable to those observed in 76 
ICP[14]; we used this model in combination with UDCA dietary supplementation to assess effects on 77 
the caecal gut microbiota to support our human results. 78 
 79 
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Results 80 
Human intestinal microbiota in normal and UDCA-treated cholestatic pregnancies 81 
To determine the effect of UDCA treatment on the composition of the gut microbiota, 82 
metataxonomics was performed on faecal samples from fourteen women with normal pregnancies, 83 
four women with untreated ICP, and seventeen women with UDCA-treated ICP (Supplementary 84 
Table S1).  85 
There was an overall increase in the relative abundance of Bacteroidetes compared with Firmicutes, 86 
the two most populous phyla in the colonic microbiota, in the women treated with UDCA (Fig. 1a, 87 
Supplementary Fig. S1). Unsupervised hierarchical clustering revealed that the faecal samples 88 
clustered into three groups according to the ratio of Bacteroidetes to Firmicutes (Fig. 1b,c), and this 89 
clustering continued to order level, revealing the same groups with the ratio of Bacteroidales to 90 
Clostridiales (Supplementary Fig. S2). Women with a high Bacteroidetes to Firmicutes ratio were 91 
more likely to be treated with UDCA than women with lower ratios (p=0.0178, Fisher’s exact test 92 
compared with both low and parity of Bacteroidetes:Firmicutes, p=0.0412, Freeman Halton 93 
extension of Fisher’s exact test compared between each cluster). For the women treated with UDCA, 94 
those with a high ratio of Bacteroidetes to Firmicutes received a greater total dose of UDCA prior to 95 
the sample being collected (p=0.004) than those with parity or a low ratio; there was no other 96 
difference between the groups (Table 1). 97 
We have previously demonstrated in mice that caecal Bacteroidetes-encoded BSH capacity increased 98 
in pregnancy and in a model of CA dietary supplementation[13]. An assay of BSH activity was 99 
therefore performed, which demonstrated that faecal samples with lower Bacteroidetes than 100 
Firmicutes indeed did have reduced enzymatic activity (p=0.0379) (Fig. 1d).  101 
 102 
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Faecal bile acid profile in women with cholestatic and normal pregnancies, demonstrating the effect 103 
of UDCA treatment 104 
Faecal samples were subsequently assayed to determine bile acid composition. In UDCA-treated 105 
women with ICP, UDCA and its metabolite, lithocholic acid (LCA), predominated (Fig. 2a). This group 106 
also had significantly higher proportions of unconjugated bile acids than those with normal 107 
pregnancies (Fig. 2b). Faecal samples with a higher ratio of Bacteroidetes:Firmicutes had significantly 108 
more bile acids per gram than those with low or parity of Bacteroidetes:Firmicutes (Fig. 2c); this was 109 
true for both unconjugated and conjugated bile acids. In turn, high BSH activity was associated with 110 
reduced taurine-conjugated bile acids (Fig. 2d). 111 
We have previously demonstrated the effect of UDCA treatment on individual serum bile acids [15], 112 
with UDCA comprising approximately 60% (42.8-69.0%, median (IQR)) of the bile acid pool in 113 
treated, and 0.3% (0.0-0.9%) in untreated women. To determine the relative effect on classical and 114 
alternative pathways of bile acid synthesis, we used this dataset to compare the ratio of CA to CDCA 115 
following treatment (Supplementary Fig. S2). The proportion of CA reduced compared to CDCA for 116 
women who had taken at least 14g UDCA (p=0.04), with 83% (15/18) with lower CA:CDCA than prior 117 
to treatment (Supplementary Table S2).  118 
Since bile acids have different potencies with respect to FXR activation, we assessed the impact of 119 
ICP on intestinal FXR signalling by measuring the serum concentration of FGF19 in a separate cohort 120 
of women with ICP and normal pregnancies given a standardised diet over 24 hours. Treatment with 121 
UDCA significantly increased peak circulating FGF19 (Fig. 2e) with a corresponding reduction in 122 
serum 7α-hydroxy-4-cholesten-3-one (C4) concentration. Similarly, the effects of the secondary 123 
metabolites of UDCA on intestinal release of GLP1 were determined using primary murine colonic 124 
cultures. Incubation with LCA and deoxycholic acid (DCA) resulted in release of GLP1 from intestinal 125 
crypts that was not seen in control incubations (Fig. 2f). 126 
 127 
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Murine model of dietary hypercholanaemia, to determine the effects of UDCA treatment 128 
To support these findings, we performed metataxonomics on the caecal content of mice fed a 129 
normal chow control diet, and diets supplemented with 0.5% CA, 0.5% UDCA and 0.5% CA plus 0.5% 130 
UDCA immediately prior to and during pregnancy. Dietary supplementation with bile acids 131 
significantly altered the composition of the gut microbiota, with mice clustering according to their 132 
diet groups (Fig. 3a,b, Supplementary Table S3, Supplementary Fig. S4). Bacterial richness decreased 133 
with supplementation with any bile acid, and diversity reduced when UDCA was included in the diet 134 
only (Supplementary Fig. S5). Increases in Proteobacteria, in particular, were seen with CA 135 
supplementation, whilst UDCA diets were associated with increased Bacteroidetes, similar to the 136 
changes observed in human faeces (Fig. 3a). Caecal bile acid levels reflected the dietary bile acid 137 
load, in particular with higher secondary bile acids produced by bacterial modification of the 138 
supplemented bile acids (deoxycholic acid (DCA) from CA, LCA from UDCA) (Fig. 3c). Conversely, ω-139 
muricholic acid (ωMCA) is produced by bacterial modification of α- and βMCA, which are produced 140 
by de novo hepatic synthesis; this was significantly lower for mice from all groups supplemented 141 
with dietary bile acids. Further, UDCA-supplemented diets resulted in higher unconjugated bile acids 142 
than control or CA supplementation alone (Fig. 3d). 143 
 Similar changes to the caecal findings were seen in the bile acid content of the corresponding 144 
murine faeces (Fig. 3e). Notable exceptions were that CA supplementation resulted in significantly 145 
higher CA levels in the faeces of supplemented mice than controls, which was not seen in the 146 
caecum; and the highly significant elevations of LCA with UDCA treatment found in the caecum were 147 
not present in the faeces. In contrast to the caecal results, CA supplementation resulted in higher 148 
levels of unconjugated bile acid than control or UDCA-fed mice (Fig. 3f). 149 
  150 
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Discussion 151 
This study has identified that UDCA-treatment in cholestatic pregnancy can alter the composition of 152 
gut microbiota, increasing the proportion of Bacteroidetes with associated increased BSH activity. 153 
This change results in an altered intestinal bile acid environment, with more unconjugated bile acids 154 
available for enhanced secondary bile acid production, and increased FGF19-mediated 155 
enterohepatic feedback. Lower C4 concentrations were consistent with increased negative feedback 156 
on de novo hepatic bile acid synthesis through fibroblast growth factor receptor 4/ beta-klotho 157 
hepatic signalling. This finding is consistent with reports of reduced serum concentrations of the 158 
endogenous primary bile acids in UDCA-treated women [15]. 159 
Observational studies of human disease are subject to many confounders, which are particularly 160 
difficult to control for in pregnancy. A limitation of this study is the interindividual variability present 161 
for the relatively small number of women participating, for whom other clear confounders have 162 
been excluded. To address this, we used a murine model of cholestatic pregnancy supplemented 163 
with oral UDCA, and examined how the caecal intestinal microenvironment was affected by UDCA 164 
treatment. At the phylum-level, UDCA-supplementation of mice resulted in similar alterations to 165 
those seen for women with ICP treated with UDCA, notably a higher proportion of Bacteroidetes 166 
with a correspondingly lower proportion of Firmicutes. Previous studies have demonstrated that 167 
dietary cholic acid-associated enrichment of the microbiota with Bacteroidetes was associated with 168 
increased bsh gene read counts, and these originated from this group of bacteria[13]. Our findings 169 
are consistent with this observation following UDCA treatment, as this resulted in higher proportions 170 
of unconjugated bile acids in the caecum compared to control mice, and no corresponding rise in 171 
taurine-conjugated bile acids, which would be expected if this resulted entirely from the additional 172 
dietary load.  173 
Ursodeoxycholic acid may reduce the non-UDCA total serum bile acids for women with ICP[8,9,15]. 174 
This mechanism of action has been attributed to increased hepatic bile acid secretion, with 175 
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enhanced choleresis secondary to vesicular exocytosis (reviewed by Beuers et al.)[16]. Herein, we 176 
provide a complementary explanation: by enhancing enterohepatic feedback via FGF19, UDCA can 177 
reduce hepatic bile acid synthesis de novo.  178 
FGF19 is produced upon bile acid ligand binding to FXR, although UDCA itself is not a strong FXR 179 
agonist in intestinal cells[17]. UDCA is modified by intestinal bacteria to produce alternative 180 
secondary bile acids; 7β-dehydroxylation results in the formation of LCA, which explains its 181 
significantly higher levels in the faeces of UDCA-treated women with ICP than other pregnant 182 
groups; but LCA also causes induction of intestinal FXR to produce FGF19[18]. UDCA can also be 183 
converted by bacterial 7α- and 7β-hydroxysteroid dehydrogenase into the potent intestinal FXR 184 
agonist chenodeoxycholic acid (CDCA)[18,19]. Although it did not reach statistical significance after 185 
adjustment for multiple comparisons, an increase in CDCA was observed in the faeces of UDCA-186 
treated women; it is likely that levels of CDCA are higher in the terminal ileum than the faeces since 187 
it is efficiently uptaken by passive diffusion, via ASBT when conjugated, or biotransformed to LCA 188 
(reviewed by Crosignani et al.)[20]. Thus, CDCA agonism may explain the increased FGF19 levels seen 189 
in UDCA-treated women. Mechanisms to safely obtain terminal ileal content samples in pregnant 190 
women would be required to support this conclusion. 191 
We confirmed that an increase in the CDCA:CA ratio occurs in the serum of women with ICP during 192 
UDCA treatment[15,21]. We conclude that hepatic bile acid synthesis via the classical pathway to 193 
produce CA is more affected by UDCA treatment than intra- and extra-hepatic synthesis of CDCA via 194 
the alternative pathway, secondary to the hepatic action of FGF19. This is consistent with the effect 195 
of FGF19 analogue administration, where the bile acid profile in mice reduces CA in favour of MCA 196 
synthesis[22]. In the murine model, treatment with UDCA alone or in combination with CA did not 197 
reduce βMCA. However, UDCA alone did reduce CA, demonstrating that its use could alter the 198 
balance of classical / alternative bile acid synthesis pathways in the liver, similar to humans. 199 
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The difference in our findings between enhancement of FGF19 release compared with the 200 
reductions seen in morbidly obese individuals treated with UDCA[23] may reflect the different 201 
underlying states of study individuals. Distal ileal FXR expression has been correlated with body mass 202 
index, with obese individuals having 3-fold higher FGF19 mRNA measured[24]. Notably, ICP is not 203 
associated with maternal obesity[25]. Furthermore, the effects of pregnancy and obesity on the 204 
composition of the gut microbiota differ considerably: pregnancy is associated with an increase in 205 
bacterial diversity and higher Bacteroidetes[13] whilst a number of studies of obesity report reduced 206 
diversity with lower Bacteroidetes[26–29]. Our findings are consistent with those following faecal 207 
microbiota transplant for the treatment of Clostridioides difficile, which results in enhanced FGF19 208 
enterohepatic feedback secondary to restoration of intestinal bacteria, in particular those encoding 209 
BSH activity[30]. Additionally, ileal apical sodium-dependent bile acid transporter (ASBT) protein 210 
levels fall in pregnancy[13], for which conjugated bile acids are the preferred substrate for bile acid 211 
uptake by the enterocyte. Thus, passive diffusion of unconjugated bile acids is likely of greater 212 
relevance in pregnancy to affect subtrate availability for intestinal FXR signalling, which is dose 213 
dependent[31]; this is consistent with findings that unconjugated bile acids (CDCA and DCA) increase 214 
FGF19 gene expression in two intestinal cell lines (Caco-2 and T84)[32]. 215 
Additionally, this study suggests a mechanism by which treatment with UDCA might improve GLP1 216 
release (and thus impaired glucose tolerance) in ICP. The marked elevation of LCA in the faeces of 217 
treated women is likely to provide a local agonist to intestinal enteroendocrine L cells, which we 218 
confirmed in explants triggers GLP1 release, likely by signalling via TGR5. This result is consistent 219 
with a recent meta-analysis of seven studies (626 participants) assessing glycaemic markers in 220 
patients treated with UDCA, which found reductions in fasting blood glucose, glycosylated 221 
haemoglobin and insulin levels compared to control patients, in studies in non-alcoholic 222 
steatohepatitis, NAFLD and type 2 diabetes mellitus[33]. 223 
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This study supports the conclusion that the secondary modifications of UDCA by bacteria to 224 
metabolically-active bile acids are important in delivering the intestinally-derived benefits of UDCA 225 
treatment in ICP. Although unconjugated UDCA is delivered to the intestines from the ingested 226 
medication for treated women, the efficiency of the enterohepatic circulation and subsequent 227 
conjugation in the liver enable subsequent biliary secretion of conjugated UDCA. Modification of this 228 
to LCA or CDCA requires cleavage from the conjugated bile acid by bacterial bile salt hydrolase. 229 
Hence, we conclude that an intestinal environment favourable to bile salt hydrolase-producing 230 
bacteria is likely to enhance enterohepatic feedback. Women with a high ratio of 231 
Bacteroidetes:Firmicutes were more likely to be taking UDCA (7/8), however others taking UDCA had 232 
a low ratio (6/14), and correspondingly reduced bile salt hydrolase activity in the faeces. This 233 
biological variation may explain the differing clinical responses to UDCA that we have observed for 234 
women with ICP[34], and provide an additional treatment target (enriching the intestinal microbiota 235 
with bile salt hydrolase-producing bacteria) to provide in combination with UDCA for the treatment 236 
of ICP. Identification of women with a high Bacteroidetes:Firmicutes signature prior to treatment 237 
may predict better response to treatment with UDCA, and future studies could use this as a 238 
predictive tool to treatment response.  Alternatively, the observation that women with a high ratio 239 
of Bacteroidetes:Firmicutes had taken significantly more UDCA prior to sample donation than those 240 
women with a lower ratio suggests that there is a dose-response to UDCA treatment that may affect 241 
the composition of the gut microbiota. The lower quartile of UDCA exposure for women with high 242 
Bacteroidetes:Firmicutes was more than 2g/day for one week, providing the first evidence for 243 
minimal effective dosing for UDCA in ICP.    244 
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Methods 245 
Human studies 246 
The study was approved by the ethics committee of Hammersmith Hospitals NHS Trust, London 247 
(08/H0707/21 and 11/LO/0396), and performed according to the principles of the 1975 Declaration 248 
of Helsinki. Written informed consent was obtained from all participants prior to inclusion in the 249 
study. Women were opportunistically recruited in the third trimester of pregnancy to donate faecal 250 
samples; these were obtained from 21 women with ICP and 14 women with uncomplicated 251 
pregnancies. ICP was confirmed by demonstration of serum bile acids >10µmol/L in association with 252 
pruritus, with no additional identifiable cause for their liver dysfunction. Women were restricted to 253 
those with spontaneously conceived third trimester singleton pregnancies, who had not taken 254 
antibiotics for the duration of the pregnancy, and did not report any other pregnancy complications. 255 
Faecal samples were frozen at -80oC within 24 hours of sample collection, and sections from the 256 
same sample used for metataxonomics, bile acid measurement and bile salt hydrolase activity 257 
assays. 258 
Serum samples were obtained from women following a standardised diet from 18:00 the preceding 259 
day. Serum FGF19 and C4 levels were analysed as previously described[13] from serum samples 260 
obtained at 15:00 (correspondent with peak FGF19) for 24 women with uncomplicated pregnancies, 261 
and 20 women with ICP (10 untreated, and 10 treated with UDCA). The measurement of individual 262 
serum bile acids was previously described in a study of the effect of UDCA treatment on serum bile 263 
acid profile[15]; we used these data to calculate the ratio of CA:CDCA for new comparison.  264 
Murine studies. 265 
The experiments were conducted according to the UK Animals (Scientific Procedures) Act of 1986, 266 
with approval of the King’s College London Animal Studies Committee. Age-matched female C57BL/6 267 
mice (Harlan Laboratories, Bicester, UK) were housed in the same room, with a 12-hour light cycle, 268 
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with 3 mice per cage according to dietary group. Mice were fed, ad libitum a normal chow (RM3, 269 
Special Diets Services, Essex, UK) control diet, or an RM3 diet supplemented with 0.5% CA, 0.5% 270 
UDCA, or 0.5% CA plus 0.5% UDCA (LBS Biotechnology, Horley, UK, n=6-7 per group), and after one 271 
week were mated. Mice were sacrificed at day 18 of pregnancy, at which time caeca and faeces 272 
were harvested, snap frozen on dry ice and stored at -80oC.  273 
Primary colonic culture secretion studies were performed as previously described[35]. In brief, male 274 
C57BL/6 mice fed a control diet were sacrificed at 10-12 weeks of age, and colons were harvested. 275 
1mm2 squares of cleaned colon were digested with collagenase from Clostridium histolyticum 276 
(Sigma-Aldrich, St Louis, US) in Dulbecco’s-modified Eagle medium (DMEM) (Sigma-Aldrich, St Louis, 277 
US), and cultured overnight on 1% Matrigel-coated plates (Corning, New York, US) and DMEM with 278 
10% fetal calf serum and 1% penicillin and streptomycin(Sigma-Aldrich, St Louis, US). Cultures were 279 
treated with 100µM LCA or 100µM DCA, and 10µM 3-isobutyl-1-methylxanthine (IBMX)/forskolin 280 
used as a positive control, for 2 hours. GLP1 concentrations were measured by ELISA (Millipore 281 
Sigma, Burlington, US) for the supernatant and lysed cells, and GLP1 release calculated as a 282 
percentage of total levels. 283 
Metataxonomic sequencing 284 
Murine caecal content was separated from overlying intestine whilst frozen with macroscopic 285 
dissection. Human faecal aliquots (200mg) and murine caecal content were lysed using the Qiagen 286 
Tissuelyser II bead beater (25Hz for 20 minutes), with DNA extracted using the QiaAMP Fast DNA 287 
Stool Mini Kit (Qiagen, Venlo, Netherlands), according to manufacturer’s instructions. 288 
16S rRNA gene sequencing was performed with the Illumina MiSeq platform (Illumina Inc., Saffron 289 
Waldon, UK). Human faecal 16S rRNA gene sequencing using V1-V3 primers was performed by 290 
Research and Testing Laboratories, Texas, as per published protocols[36], whilst murine caecal 16S 291 
rRNA gene sequencing was performed using V1-V2 primers in house[37]. Murine caecal sample 292 
libraries were cleaned and normalised using the SequalPrep Normalization Plate Kit (Life 293 
14 
 
Technologies, Paisley, UK). Sample library quantification was performed with the NEBNext Library 294 
Quant Kit for Illumina (New England Biolabs, Hitchin, UK), and 300bp paired-end sequencing 295 
performed using the MiSeq Reagent Kit v3 (Illumina). Data were analysed using Mothur 296 
software[38], with nucleic acid sequences aligned using the SILVA database[39] and classified using 297 
the ribosomal data project (RDP) database reference sequence files according to Wang et al.[40].  298 
Statistical analyses were performed in R, using the Vegan package to perform non-metric 299 
multidimensional scaling (NMDS) and permutational multivariate analysis of variation 300 
(PERMANOVA). The Statistical Analysis of Metagenomic Profiles (STAMP) software was used to 301 
compare groups at taxonomic levels, using the Kruskal-Wallis H-test with Tukey-Kramer post hoc 302 
testing and correction for multiple testing with Benjamini-Hochberg FDR. Alpha diversity (Shannon 303 
diversity index) and richness (total number of bacterial taxa observed) calculated in Mothur were 304 
compared using SPSS version 23 (IBM, New York, USA). 305 
Bile salt hydrolase activity assay 306 
Faecal water was prepared and total faecal protein quantified similarly to a method previously-307 
described[41], but with the addition of bacterial and mammalian protease inhibitor cocktails (G 308 
Biosciences, Uttar Pradesh, India), as well as Dithiothreitol to 1mM final concentration (Roche, Basel, 309 
Switzerland) (to minimise enzyme oxidation[42]). 310 
The bile salt hydrolase assay has been described previously[39]. In brief, BSH activity was 311 
determined by measuring insoluble DCA precipitated (determined by absorbance at 600nm (A600)) 312 
following incubation of 500µg of faecal protein with taurodeoxycholic acid (Sigma-Aldrich, St Louis, 313 
US). Samples were compared with a standard curve of known DCA concentrations and measured in 314 
triplicate. 315 
Bile acid quantification 316 
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Faecal and caecal samples were homogenized in methanol (containing internal standards) with 317 
ceramic beads using the Qiagen Tissuelyser II as previously described[43]. Following centrifugation, 318 
20 µL supernatant was diluted with 980 µL MeOH:H2O 1:1. Bile acids were separated and detected 319 
using ultra-performance liquid chromatography coupled to mass spectrometry, as previously 320 
reported[43]. Quantification was made using an external standard curve. 321 
Statistical analyses 322 
Where not otherwise indicated in the methods, results were compared using GraphPad Prism 323 
(version 7.02) using Fisher’s exact test, analysis of variation (ANOVA) and Tukey’s multiple 324 
comparisons test (accounting for multiple measures), Kruskal-Walllis test with Dunn’s multiple 325 
comparisons test (accounting for multiple measures), multiple t test with Holm-Sidak correction for 326 
multiple comparisons or Mann-Whitney tests, dependent upon normality of data. 327 
Data availability 328 
The datasets generated during the current study are available from the corresponding author on 329 
reasonable request.  330 
 331 
  332 
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Figure legends 462 
Figure 1. The faecal microbiota profiles of cholestatic and uncomplicated pregnancy cluster 463 
according to the ratio of Bacteroidetes to Firmicutes 464 
(a) Distribution of microbes at phylum level in women with normal pregnancies (n=14), women with 465 
intrahepatic cholestasis of pregnancy (ICP) treated with ursodeoxycholic acid (UDCA, n=17), and 466 
women with untreated ICP (n=4). 467 
(b) Heat map demonstrating unsupervised clustering of faecal samples by microbiota profiles 468 
determined from 16S rRNA gene sequencing, according to B:F (the ratio of Bacteroidetes to 469 
Firmicutes). Each row refers to faecal samples from individual women as per (a), uncomplicated 470 
pregnancy: blue status; ICP treated with UDCA: purple status; untreated ICP: green status; red status 471 
shows methodological control. Box colours show relative bacterial abundance, dark blue reflecting 472 
minimal sequences present in samples – red showing high sequence levels in samples. 473 
(c) NMDS analysis of 16S rRNA gene sequences from human faecal samples as per (a), demonstrating 474 
clustering according to ratio of Bacteroidetes to Firmicutes (B:F). Red: high B:F, blue: low B:F, green: 475 
parity of B:F. 476 
(d) Bile salt hydrolase activity of human faecal samples as per (a), according to ratio of Bacteroidetes 477 
to Firmicutes (B:F), determined by nmol of deoxycholic acid (DCA) production per mg of protein per 478 
minute. Tukey box-plots show median, IQR and whiskers at 1.5 IQR. Significance determined by one-479 
way ANOVA with Tukey post hoc comparison, ANOVA (F(2,32 = 3.55), p=0.040); * p=0.038. 480 
Figure 2. Women treated with ursodeoxycholic acid for cholestatic pregnancy have altered faecal 481 
bile acids and enhanced enterohepatic feedback 482 
(a) Faecal bile acids from women in the third trimester of uncomplicated pregnancy (blue boxes, 483 
n=14), untreated ICP (green boxes, n=4), and ICP treated UDCA (purple boxes, n=17). Groups were 484 
compared with 2-way ANOVA with Tukey’s multiple comparisons test; ****adjusted p<0.0001, 485 
*adjusted p=0.0294. CA: cholic acid, CDCA: chenodeoxycholic acid, DCA: deoxycholic acid, LCA: 486 
lithocholic acid, MCA: muricholic acid, HCA: hyocholic acid, HDCA: hyodeoxycholic acid, MDCA: 487 
murideoxycholic acid, TCA: taurocholic acid, TCDCA: taurochenodeoxycholic acid, TDCA: 488 
taurodeoxycholic acid, TLCA: taurolithocholic acid, TUDCA: tauroursodeoxycholic acid, TβMCA: 489 
taurobetamuricholic acid, GCA: glycocholic acid, GCDCA: glycochenodeoxycholic acid, GDCA: 490 
glycodeoxycholic acid, GLCA: glycolithocholic acid, GUDCA: glycoursodeoxycholic acid.  491 
23 
 
(b) Faecal bile acids by conjugation, from samples as per (a). Groups were compared with 2-way 492 
ANOVA with Tukey’s multiple comparisons test; ***adjusted p=0.0003, *adjusted p=0.0277.  493 
(c) Faecal bile acid levels according to ratio of Bacteroidetes to Firmicutes (B:F), determined by 494 
unsupervised clustering, from samples as per (a). Groups compared with Kruskal-Wallis test with 495 
Dunn’s multiple comparisons test; **adjusted p=0.0086, *adjusted p=0.0470.  496 
(d) Faecal bile acid levels by conjugation according to bile salt hydrolase (BSH) activity. Low BSH 497 
activity (white boxes): 0.00-0.83 nmol DCA/mg/min (n=24), high BSH activity (grey boxes): 2.23-5.31 498 
nmol DCA/mg/min (n=11). Groups compared with Mann-Whitney tests, *p=0.0106.  499 
(e) Serum fibroblast growth factor 19 (FGF19) and 7α-hydroxy-4-cholesten-3-one (C4) 500 
concentrations from women in the third trimester of uncomplicated pregnancy (blue boxes, n=24), 501 
untreated ICP (green boxes, n=10) and UDCA-treated ICP (purple boxes, n=10). Samples were taken 502 
at 15:00, following a standardized diet for 21 hours. Groups compared with multiple t tests, and 503 
Holm-Sidak correction for multiple testing. For FGF19: *p=0.0302, for C4: normal vs ICP on UDCA 504 
*p=0.0296, ICP untreated vs ICP on UDCA *p=0.0335. 505 
(f) Percentage of glucagon-like peptide one (GLP1) released from murine colonic tissue on exposure 506 
to the bile acids LCA and DCA. Negative control – buffer only, positive control: 10µM 3-isobutyl-1-507 
methylxanthine (IBMX) with 10µM forskolin (n=4, with 7-8 replicates per experiment). 508 
Boxes show median and interquartile range (IQR), with whiskers at 1.5 IQR.  509 
Figure 3. Ursodeoxycholic acid dietary supplementation for pregnant mice increases caecal 510 
Bacteroidetes and unconjugated bile acids 511 
(a) Distribution of microbes at phylum level in day 18 pregnant mice given a normal chow (control) 512 
diet (n=7), 0.5% cholic acid (CA) supplemented diet (n=7), 0.5% ursodeoxycholic acid (UDCA) 513 
supplemented diet (n=6) and 0.5% CA + 0.5% UDCA supplemented diet (n=7). 514 
(b) NMDS plot demonstrating distribution of gut microbiota according to diet, for mice as per (a). 515 
(c) Caecal bile acids from pregnant mice as per (a). Control: blue boxes, 0.5% CA diet: green boxes, 516 
0.5% UDCA diet: purple boxes, 0.5% CA + 0.5% UDCA diet: pink boxes. DCA: deoxycholic acid, LCA: 517 
lithocholic acid, MCA: muricholic acid, HDCA: hyodeoxycholic acid, MDCA: murideoxycholic acid, 518 
TCA: taurocholic acid, TUDCA: tauroursodeoxycholic acid, TβMCA: tauro-betamuricholic acid, 519 
TωMCA: tauro-omegamuricholic acid TαMCA: tauro-alphamuricholic acid. 520 
(d) Caecal bile acids by conjugation, from pregnant mice as per (a). Control: blue boxes, 0.5% CA 521 
diet: green boxes, 0.5% UDCA diet: purple boxes, 0.5% CA + 0.5% UDCA diet: pink boxes.  522 
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 (e) Faecal bile acids from pregnant mice as per (a). Control: blue boxes, 0.5% CA diet: green boxes, 523 
0.5% UDCA diet: purple boxes, 0.5% CA + 0.5% UDCA diet: pink boxes.  524 
(f) Faecal bile acids by conjugation, from pregnant mice as per (a). Control: blue boxes, 0.5% CA diet: 525 
green boxes, 0.5% UDCA diet: purple boxes, 0.5% CA + 0.5% UDCA diet: pink boxes.  526 
Groups were compared with 2-way ANOVA with Tukey’s multiple comparisons test; adjusted p 527 
values where p<0.05: a control vs CA; b control vs UDCA; c control vs CA+UDCA, d CA vs UDCA; e CA 528 
vs CA+UDCA; f UDCA vs CA+UDCA. Boxes show median and interquartile range (IQR), with whiskers 529 
at 1.5 IQR.  530 
 531 
Tables 532 
Table 1. Clinical features of women treated with UDCA based upon the ratio of Bacteriodetes to 533 
Firmicutes 534 
 High B:F (n=7) 
Median (IQR) 
Low or Parity B:F (n=10) 
Median (IQR) 
Comparison 
Maternal age (years) 36  
(34 to 40) 
35  
(29 to 38) 
ns 
Gestation itch 
commenced 
(week+day) 
28+3 
(21+0 to 29+0) 
32+4  
(29+0 to 34+4) 
ns 
Gestation of sample 
(week+day) 
35+5  
(30+5 to 36+5) 
36+5 
(34+4 to 37+1) 
ns 
UDCA total dose prior 
to sample (g)* 
76  
(15 to 92) 
10  
(1 to 19) 
p=0.004 
Peak bile acid 
concentration pre-
sample (µmol/L) 
65  
(41 to 214) 
40  
(26 to 75) 
ns 
Bile acid 
concentration at time 
of sample (µmol/L) 
46  
(21 to 136) 
29  
(19 to 50) 
ns 
Peak bile acid 
concentration 
throughout 
pregnancy (µmol/L) 
78  
(64 to 254) 
60  
(29 to 109) 
ns 
B: Bacteroidetes; F: Firmicutes; n: number; IQR: interquartile range; ns: not significant. *total UDCA 535 
dose assuming 100% compliance, calculated using prescribed dose(s) and duration. Comparisons using 536 
two-tailed student’s t-tests, p<0.05 defined as threshold of significance. 537 
